Keros Therapeutics (KROS) Earnings Date & Reports

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

KROS is expected to report earnings to rise 15.70% to -139 cents per share on August 12

Keros Therapeutics KROS Stock Earnings Reports

Q2'26

Est.

$-1.40

Q1'26

Missed

by $0.18

Q4'25

Missed

by $0.16

Q3'25

Beat

by $0.87

Q2'25

Beat

by $0.37

The last earnings report on May 14 showed earnings per share of -121 cents, missing the estimate of -102 cents. With 267.99K shares outstanding, the current market capitalization sits at 217.51M.

View a ticker or compare two or three

Compare

KROS

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for KROS